ArticleDiscover oncology2025
Risk prediction of second primary malignancies in patients with primary gastric neuroendocrine neoplasms: a population-based study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposePatients with gastric neuroendocrine neoplasms (GNENs) face elevated risks of second primary malignancies (SPMs), yet tools for personalized risk prediction are lacking. This study aimed to explore the risk factors associated with the development of SPMs in patients with GNENs and to establish a new competing-risk nomogram to predict the occurrence of SPMs.
methodsWe obtained clinical data for GNENs patients from the Surveillance, Epidemiology, and End Results (SEER) database covering the period from 2000 to 2015. Using Fine and Gray's proportional sub-distribution hazards model, potential risk factors for SPM development in GNENs' patients were identified. A competing-risk nomogram was then constructed to quantify the probability of SPMs' occurrence and was evaluated using the area under the receiver-operating characteristic (ROC) curves (AUC) and calibration curves.
resultsAmong the 5160 GNENs patients, 18.7% developed SPMs during a maximum follow-up period of approximately 131 months (median 82 months). Independent risk factors for SPMs included age, marital status, tumor size, histopathological grade, disease extent, and T staging. The nomogram based on these factors demonstrated relatively strong predictive accuracy.
conclusionThis study identifies key risk factors for SPMs in GNENs patients and introduces a nomogram that effectively predicts SPM risk. This tool may help clinicians better assess patient risk and guide treatment decisions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.